These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33896088)

  • 1. Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy.
    Camargo JF; Mendoza MA; Lin R; Moroz IV; Anderson AD; Morris MI; Natori Y; Natori A; Raja M; Lekakis L; Beitinjaneh A; Jimenez A; Goodman M; Wang T; Komanduri KV; Pereira D
    Transpl Infect Dis; 2021 Aug; 23(4):e13625. PubMed ID: 33896088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
    Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
    Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre-Cellular Therapy SARS-CoV-2 Infection.
    Nimgaonkar I; Yoke LH; Roychoudhury P; Flaherty PW; Oshima MU; Weixler A; Gauthier J; Greninger AL; Mielcarek M; Boeckh M; Liu C; Hill JA
    Clin Infect Dis; 2024 Jul; 79(1):86-95. PubMed ID: 38427848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients.
    Al-Ramahi JS; Shahzad M; Li K; DeJarnette S; Chaudhary SG; Lutfi F; Ahmed N; Balusu R; Bansal R; Abdelhakim H; Shune L; Singh AK; Abhyankar SH; McGuirk JP; Mushtaq MU
    Leuk Lymphoma; 2023 Dec; 64(12):1981-1991. PubMed ID: 37574842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection.
    Shah N; Dahi PB; Ponce DM; Sauter CS; Shaffer BC; Chung DJ; Politikos I; Lin RJ; Giralt SA; Papanicolaou G; Ramanathan LV; Perales MA; Kamboj M; Shah GL; Gyurkocza B
    Transplant Cell Ther; 2022 Jan; 28(1):55.e1-55.e5. PubMed ID: 34649021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    Clin Infect Dis; 2024 Aug; 79(2):542-554. PubMed ID: 38801746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study.
    Averbuch D; de la Camara R; Tridello G; Knelange NS; Bykova TA; Ifversen M; Dobsinska V; Ayas M; Hamidieh AA; Pichler H; Perez-Martinez A; Cesaro S; Sundin M; Badell I; Bader P; Johansson JE; Mirci-Danicar O; Sedlacek P; Paillard C; Gibson B; Lawson S; Kroeger N; Corbacioglu S; Mikulska M; Piñana JL; Styczynski J; Ljungman P
    Bone Marrow Transplant; 2023 May; 58(5):558-566. PubMed ID: 36849806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Mittal A; Solera JT; Ferreira VH; Kothari S; Kimura M; Pasic I; Mattsson JI; Humar A; Kulasingam V; Ierullo M; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2023 Nov; 29(11):706.e1-706.e7. PubMed ID: 37582470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.
    La Rosa C; Chiuppesi F; Park Y; Zhou Q; Yang D; Gendzekhadze K; Ly M; Li J; Kaltcheva T; Ortega Francisco S; Gutierrez MA; Ali H; Otoukesh S; Amanam I; Salhotra A; Pullarkat VA; Aldoss I; Rosenzweig M; Aribi AM; Stein AS; Marcucci G; Dadwal SS; Nakamura R; Forman SJ; Al Malki MM; Diamond DJ
    Front Immunol; 2023; 14():1114131. PubMed ID: 36936918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group.
    Schaffrath J; Brummer C; Wolff D; Holtick U; Kröger N; Bornhäuser M; Kraus S; Hilgendorf I; Blau IW; Penack O; Wittke C; Steiner N; Nachbaur D; Thurner L; Hindahl H; Zeiser R; Maier CP; Bethge W; Müller LP
    Transplant Cell Ther; 2022 Jun; 28(6):337.e1-337.e10. PubMed ID: 35296445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
    Tan JY; Wee LE; Tan YH; Conceicao EP; Lim FWI; Chen Y; Than H; Quek JKS; Nagarajan C; Goh YT; Hwang WYK; Phua GC; Chung SJ; Tan TT; Linn YC; Ho AYL; Tan BH
    Transpl Infect Dis; 2023 Jun; 25(3):e14024. PubMed ID: 36715661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
    Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
    Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study.
    Bhatt NS; Sharma A; St Martin A; Abid MB; Brown VI; Diaz Perez MA; Frangoul H; Gadalla SM; Herr MM; Krem MM; Lazarus HM; Martens MJ; Mehta PA; Nishihori T; Prestidge T; Pulsipher MA; Rangarajan HG; Williams KM; Winestone LE; Yin DE; Riches ML; Dandoy CE; Auletta JJ
    Transplant Cell Ther; 2022 Oct; 28(10):696.e1-696.e7. PubMed ID: 35798233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics.
    Rosen EA; Krantz EM; McCulloch DJ; Wilson MH; Tverdek F; Kassamali Escobar Z; Drucker D; Sanchez E; Ueda Oshima M; Mielcarek M; Gauthier J; Pergam SA; Hill JA; Liu C
    Transplant Cell Ther; 2024 Nov; 30(11):1108.e1-1108.e11. PubMed ID: 39179107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
    Khawaja F; Papanicolaou G; Dadwal S; Pergam SA; Wingard JR; Boghdadly ZE; Abidi MZ; Waghmare A; Shahid Z; Michaels L; Hill JA; Kamboj M; Boeckh M; Auletta JJ; Chemaly RF
    Transplant Cell Ther; 2023 Jan; 29(1):10-18. PubMed ID: 36273782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
    Passweg JR; Baldomero H; Ansari M; Arber C; Chalandon Y; Daskalakis M; Diepold M; Diesch-Furlanetto T; Duchosal MA; Gerull S; Güngör T; Heim D; Hitz F; Holbro A; Masouridi-Levrat S; Nair G; Novak U; Pabst T; Renner C; Stussi G; Schneidawind D; Schanz U; Wannesson L; Halter JP;
    Hematol Oncol; 2024 Jan; 42(1):e3241. PubMed ID: 38058031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.
    Shahzad M; Chaudhary SG; Zafar MU; Hassan MA; Hussain A; Ali F; Anwar I; Ahmed M; Ahmed N; Khurana S; Rauf MA; Anwar F; Hematti P; Callander NS; Abhyankar SH; McGuirk JP; Mushtaq MU
    Transpl Infect Dis; 2022 Apr; 24(2):e13792. PubMed ID: 35030267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study.
    Fan S; Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Zhang Y; Cheng Y; Sun Y; Chen Y; Chen Y; Han W; Wang J; Wang F; Xu Z; Huang X
    Ann Hematol; 2024 Apr; 103(4):1333-1344. PubMed ID: 38381172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.